Analysts at StockNews.com initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, Piper Sandler reissued a “neutral” rating on shares of Infinity Pharmaceuticals in a report on Friday, February 24th.
Infinity Pharmaceuticals Stock Down 6.6 %
Shares of INFI opened at $0.19 on Friday. The company has a 50-day moving average price of $0.49 and a two-hundred day moving average price of $0.79. The stock has a market cap of $16.52 million, a price-to-earnings ratio of -0.36 and a beta of 1.36. Infinity Pharmaceuticals has a 12 month low of $0.17 and a 12 month high of $1.76.
Institutional Investors Weigh In On Infinity Pharmaceuticals
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
- Get a free copy of the StockNews.com research report on Infinity Pharmaceuticals (INFI)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.